Not many prostate bispecifics in the oral sessions at ASCO this year. Most of the activity was in the posters. Four programs, four targets: 🔬 STEAP1 × CD3, xaluritamig abiraterone (Sumey, 5070): the only one with efficacy data. PSA50 65%, RECIST ORR 57% in taxane-naïve mCRPC. Inphase 3 XALience. 🔬 KLK2 × CD3, pasritamig docetaxel (PASenger, TPS5139): already in randomized phase 3, n=800, rPFS primary. 🔬 DLL3 × CD3, tarlatamab (TIDAL, TPS5142): phase 2 in DLL3-positive neuroendocrine prostate, a setting with few options. 🔬 VEGF × PD-1, ivonescimab (NCT06567314): not a T-cell engager, testing the microenvironment in mCRPC. The targets are diversifying (STEAP1, KLK2, and DLL3 each handle prostate specificity differently), and the trials are moving earlier rather than sitting late salvage. Excited to follow this movement and the idea of an immune based therapy in this typically immune resistant tumor. #ProstateCA #mCRPC #GUonc #ASCO26 @OncoAlert

Rad2Nivo: Phase Ib study of Ra-223 with Nivo in mCRPC @urotoday #ASCO26 @ggebraelmd @neerajaiims @maughanonc 🌟n=35 🌟Gr 3-5 TEAEs: 38% 🌟VAF reduction: 15/25 (60%) 🌟Median PSA PFS: 3.15 mos (95% CI 2.79-4.70)

Breaking news #ASCO26 👉Ph3 PROTEUS trial👉Periop ADT apalutamide in high-risk localized/locally advanced #prostatecancer undergoing radical prostatectomy👉↑ pathologic response (8.9% vs 1.0%) & 5-yr metastasis-free survival (78.2% vs 73.5%; HR 0.80) @urotoday @OncoAlert

Over a year ago we lost Felix, a giant in Cancer research to ….Cancer. Let us support @ASCO with a CDA in the honor of Dr Feng. support.conquer.org/p2p/site… #ASCO26 @OncoAlert @ConquerCancerFd

We need a lot more of these ribbons #ASCO26

Another banner year at ASCO for our fellowship, with six Young Investigator Awards awarded to our trainees. Congratulations to our outstanding fellows on this well-deserved recognition!

Unsung hero poster award for RCC. @OncHahn discusses muscle and fat changes in patient receiving either Len/Ev or Cabo with some interesting findings that complement standard toxicity data.

ABBV-969 delivered a median rPFS of 15.3 months (95% CI 9.8, NE) in heavily pretreated mCRPC, in patients who had already progressed on taxanes and/or PSMA radioligand therapy. First-in-human dose escalation, biomarker-unselected. Median follow-up 13.7 mo. 🎯 Confirmed ORR 44.8%, including 17% CR, median DOR 11.0 mo 🎯 PSA50 67.4% and PSA90 30.2% at doses ≥3 mg/kg, median DoR 10.8 mo 📊 Responses across liver, lung, and nodal lesions 🔍 Manageable safety: anemia (59%) and fatigue (53%) most common, Grade ≥3 TRAEs 46.9%. ILD/pneumonitis only at the top dose, which has been dropped Real activity in a post-taxane, post-RLT population that is running out of options. Dose optimization ongoing. Congrats to the authors. @TDorffOnc #ProstateCA #mCRPC #GUonc #ASCO26

Today, history was made #ASCO26 The results of #RASOLUTE302 were reported: median overall survival doubled for previously treated patients with metastatic #PancreaticCancer. As the room erupted in a well-deserved standing ovation, my thoughts went immediately to my high school friend, Cati. Cati died from metastatic pancreatic cancer less than a month after her diagnosis last year. She was only 37 years old & one of the kindest people I’ve ever known. She left behind her husband, young son, and countless family members and friends who loved her deeply. Cancer research never moves as quickly as any of us wish it would. Cati should still be here. But every breakthrough represents hope. Hope for more time, more memories, and more tomorrows. Tonight, I'm thinking of Cati and everyone we've lost while we continue pushing for better outcomes for all patients. 💜

Special moment #ASCO26 Proud & honored to receive the FASCO designation & celebrate w outstanding colleagues Grateful to be part of this incredible community Thanks @PauloBergerot for your constant support, and @montypal for your mentorship & countless opportunities

👏 A great example of using outcomes that matter to patients to drive research questions. Thanks @MRHarrisonMD @DukeCancer for talking us through your poster on how quality of life influences mRCC outcomes! #ASCO26

Grateful for the kind words, @CananDirican. This panel reminded me why I love doing this work in community. The conversation around translating GU oncology data into real-world decision-making is one we need to keep having, especially as the treatment landscape in prostate, bladder, and kidney cancer moves faster than most guidelines can track. More to come from #ASCO26. @PGrivasMDPhD @CParkMD #GUonc @GUOncologyNow

Cheers to @neerajaiims on his presentation of the #TALAPRO3 data w simultaneous @NEJM publication! It reflects the dream of many clinical investigators in #oncology - to lead a trial & generate paradigm shifting data in a field that you have devoted your life to (in this case, #prostatecancer). If you see him at #ASCO26, inquire about his remarkable story. At @huntsmancancer, he built the GU program from scratch into one of the highest performing programs worldwide. He did this over the span of nearly two decades through mentorship of his faculty & fellows (@umangtalking @maughanonc @ziremozay @ggebraelmd et al), extensive outreach to the local community & active participation & leadership in multiple studies (a mix of industry, ISTs & @SWOG). Simply amazing.

Breaking news #ASCO26 Adding Talazoparib to enzalutamide significantly ⬆️ rPFS 👉 HR 0.48 in pts w/ mCSPC (mAPMS) #prostatecancer w/ HRRm 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @OpenMedicineHQ

@GUconference transforms scientific exchanges among med oncologists, rad oncs, and urologist into . . well. . a rhinestone-studded country-music infused affair. So engaging it won award for best new medical conf format & best belt buckles. Dec 3-5 #ASCO26 @CaPsurvivorship

The incredible @ARosen380 on a @SusanGKomen panel on #AYACancers at #ASCO26 talking about the lack of survivorship planning for long-term survivors. “I had to create my own survivorship plan.” As patients like Allison and I live longer, we’re putting the wheels on the bus while the bus is on the road. This is even more challenging for patients like us who aren’t seen in AYA settings. It’s going to take us all - patients, PCPs, oncs, surgeons, etc - to solve this.

The 3.5yr OS from EV302 continues to show transformative benefit (HR 0.53 (0.45-0.63)) #ASCO26 for EV/pembro. The landmark OS for the CR population (30%) is ~90%. Median time to CR is 4.5 months (responses mature over time). Response rates of platinum chemo after EVP is 21% (OS 11 months). This should be considered a 2nd line standard. Median duration of EV was 7 months - longer in responders. Optimal duration of EV trials are needed. @OncoAlert

🎉 We’re so excited to be back for #ASCO26! Please come visit our booth in the exhibit hall for resources and information for your patient and fun swag!

Just activated for accrual👉@SWOG S2419/Biofront ph3 trial in new mRCC #kidneycancer 👉frontline IO based Rx CBM-588 or placebo. @PBarataMD @montypal @DrVaishampayan @slernerbcmedu1 Practical considerations & Why open this trial👇@kidneycan @DrChoueiri

Ab#5060 @ASCO #ASCO26 by @ggebraelmd @Huntsman_GU👉bit.ly/4uXfExT👉Ph1b Rad2Nivo trial👉Radium for 2 cycles followed by Nivo/Radium for 4 cycles followed by Nivo alone➡️60% of pts w/ mean ctDNA VAF reduction #prostatecancer👇@maughanonc @OncoAlert @urotoday @PCF_Science